REGN Stock Analysis: Buy, Sell, or Hold?
REGN - Regeneron Pharmaceuticals Inc
$834.04
7.40 (0.90%)
▲
5d:
+3.8%
30d:
+27.94%
90d:
+29.79%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When REGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: REGN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: REGN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$786.46
Based on -0.5% avg growth
INTRINSIC VALUE TODAY
$488.33
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: REGN is currently trading at $834.04, which is considered extended relative to its 30-day fair value range of $673.94 to $805.21. The stock's valuation (Forward PE: 16.0) is in line with its historical norms (16.0). Remarkably, the market is currently pricing in an annual earnings decline of 0.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, REGN is in a uptrend. The price is approaching resistance at $847.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: REGN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, REGN is in a uptrend. The price is approaching resistance at $847.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: REGN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$673.94 -
$805.21
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
23.8%
Protect Your Profits
REGN is technically overbought (RSI 76). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($833.54)
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$673.94 -
$805.21
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$775.83
Resistance Level
$847.00
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.99
Wall Street Target
$833.54
(+3.4%)
Revenue Growth (YoY)
16.7%
Earnings Growth (YoY)
-4.5%
Profit Margin
27.9%
Valuation Discount vs History
-0.1% cheaper
PE vs Historical
16.0 vs 16.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.1%
(market-implied from PE analysis)
1-Year Target
$805.16
(0%)
2-Year Target
$804.36
(0%)
3-Year Target
$803.55
(0%)
3-Yr Target (if PE normalizes)
(PE: 16→16)
$803.99
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: -4.9%)
$876.58
(+9%)
Base:
(SPY PE: 16.0, Growth: -4.9%)
$692.91
(-14%)
Bear:
(PE: 13.6, Growth: -4.9%)
$588.98
(-27%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 19.72 | Current EPS (TTM): $40.46
Bull Case
$1093.45
(+31%)
Analyst growth 24.6%, PE expands to 21.7
Base Case
$994.05
(+19%)
Market implied 24.6%, PE stable at 19.7
Bear Case
$542.63
(-35%)
Severe decline -20.0%, PE contracts to 16.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.0 to 16.0
Stabilization Target:
$806.41
(+0.1%)
PE Expansion Potential:
+0.1%
Share & Embed Analysis
Last updated: August 23, 2026 1:29 AM ET
Data refreshes hourly during market hours. Next update: 2:29 AM
Data refreshes hourly during market hours. Next update: 2:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is REGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$109 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
Advanced REGN Option Strategies
Professional options setups generated by AI based on today's REGN price and gamma walls.
